Description
UNLOXCYT (cosibelimab) is a monoclonal antibody that blocks PD-L1 to help the immune system fight cancer cells. It's given as an intravenous injection, with each vial containing 300 mg in 5 mL. Manufactured by Checkpoint Therapeutics, Inc., it's approved for prescription use. This information was generated using AI and is provided for informational and research purposes only.
Resources
| Name |
Format |
Description |
Link |
|
21 |
Access the FDA dataset for Cosibelimab — ANDA 761297 submitted by Mylan Institutional LLC
|
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761297 |
Tags
- drug-information
- health-care
- drug-manufacturers
- public-health
- medications